Financial Health Assessment: PROTEC CAMERFIELD LIMITED

1. Financial Health Score: D+

Explanation: The patient has been in intensive care but is showing signs of stabilisation thanks to substantial life support from its parent company (Protec Fire Detection Plc, part of the Bosch Group). While the vital signs are improving, the underlying operational health remains fragile — the business is still loss-making at the operating level, margins are anaemic, and the balance sheet carries significant debt. Recovery is underway, but the patient remains in a critical ward rather than being discharged to full health.

2. Key Vital Signs

Vital Signs Interpretation:

Heartbeat (Revenue): The patient's heart is beating stronger — 18% revenue growth is encouraging and suggests market demand exists for the company's fire suppression services. However, a strong heartbeat means little if the circulatory system is leaking profit.

Blood Pressure (Cash Position): Cash at £3.63m is relatively healthy, up dramatically from the dangerously low £409k in 2023. This is the equivalent of a blood transfusion — necessary for survival, but the underlying condition causing the blood loss must still be addressed.

Cholesterol (Leverage): At 87% liabilities-to-assets, this patient has severely clogged arteries. For every £1 of assets, 87p is claimed by creditors. This leaves almost no buffer for unexpected shocks.

Temperature (Profitability): The patient's temperature is still elevated, indicating infection. A gross margin of 4.67% on construction/installation work is dangerously thin — most healthy competitors in this sector operate at 15-25% gross margins. The negative EBIT of £1.6m means the business is still burning cash operationally.

3. Diagnosis

Primary Condition: Chronic Margin Deficiency with Acute Project Loss Episodes

The financial data reveals a company that has suffered from what I would diagnose as "toxic project syndrome" — a condition where a small number of loss-making contracts infect the entire body corporate, dragging overall profitability into negative territory. The directors themselves confirm this, noting "a few known and isolated loss-making projects" as the primary cause.

Historical Progression — The Patient's Medical Records:

Symptoms of Distress:

1. Negative Gross Profit in 2024: A gross margin of -10.06% is the equivalent of a patient whose body is rejecting nutrients. The company was paying more to deliver projects than it was earning — a fundamentally unsustainable position.

2. Persistent Operating Losses: Even in 2025 with improved gross margins, the EBIT remains negative at -£1.6m. The company is still spending more than it earns.

3. Balance Sheet Fragility: Net assets of £336k on a £22.1m revenue business represents equity of just 1.5% of turnover. This is paper-thin and provides virtually no cushion against future project losses.

4. Dependency on Parent Company: The £4m equity injection in 2025 (following £3m in 2024) is akin to a patient requiring repeated blood transfusions. Without parental support, this business would likely have entered insolvency proceedings.

5. Long-term Contract Recoverability: Amounts recoverable on long-term contracts increased from £5.8m to £7.3m. While this represents future revenue, it also represents future risk — these contracts must be managed carefully to avoid repeating past losses.

Positive Signs of Recovery:

1. Revenue Growth: 18% increase suggests market position is strengthening
2. Gross Margin Improvement: Moving from -10% to +4.67% is significant progress
3. Cost Reduction: Sales & General Expenses reduced from £4.0m to £2.5m — a 37.5% reduction showing disciplined cost management
4. Management Restructuring: New directors appointed in January and March 2025, suggesting the parent company is taking decisive action
5. Strategic Pivot: Moving away from large-scale sprinkler projects toward mechanical suppression, service, and small works — a sensible de-risking strategy
6. Bosch Group Backing: The parent company's financial strength provides a safety net and access to global supply chains

4. Prognosis

Short-term Outlook (6-12 months): Cautiously Optimistic

The patient is responding to treatment. The restructuring, new management team, and strategic pivot toward higher-margin, lower-risk work are appropriate interventions. The Bosch Group's continued support appears committed, and the cash position provides breathing room.

However, the patient remains vulnerable to: - Further project losses if risk management processes fail - Market downturn reducing construction activity - Skilled labour shortages in a competitive environment - Input cost inflation eroding thin margins

Medium-term Outlook (1-3 years): Guarded

The directors' confidence that the business will "bounce from setbacks faced in 2024 & 2025 and achieve sustained growth" is plausible but not yet proven. The key risk is whether the cultural and operational changes can truly transform project delivery and margin performance. Construction and installation businesses can easily slip back into loss-making if project estimation and execution are not rigorously controlled.

5. Recommendations

Immediate Treatment (0-6 months):

1. Strict Project Governance: Implement the "structured risk management analysis and approval process" mentioned in the strategic report with rigour. No large projects should proceed without detailed margin analysis and board approval. This is the equivalent of putting the patient on a strict diet — no more toxic projects.

2. Cash Conservation: Despite the healthy cash position, this is primarily parent company money. Maintain tight working capital management and avoid over-extending on contract commitments.

3. Margin Monitoring: Establish weekly or bi-weekly project margin reviews. With gross margins at only 4.67%, even small cost overruns can eliminate profitability entirely.

Medium-term Rehabilitation (6-18 months):

4. Service Revenue Growth: Accelerate the pivot toward service, maintenance, and small works. These typically carry higher margins (20-30%) and provide recurring revenue — the equivalent of building muscle mass rather than relying on occasional heavy lifts.

5. Pricing Discipline: The strategic report mentions "price increases are to be passed on to the market." Ensure this is done systematically and not selectively. The current margin does not allow for any discounting.

6. Integration with Sister Companies: Leverage the Bosch Group's "integrator" approach to cross-sell services and share operational best practices. The family of companies should provide referrals and combined offerings.

Long-term Health Maintenance:

7. Target Margin Recovery: Set clear targets to restore gross margins to at least 12-15% within 2-3 years. This will require both better project selection and improved execution.

8. Balance Sheet Strengthening: Aim to rebuild net assets to at least 10-15% of turnover (£2.2m-£3.3m) before considering any dividend payments or expansion.

9. Risk Diversification: Continue the strategic shift away from dependency on large projects. A portfolio of smaller, higher-margin contracts provides natural diversification.

10. KPI Dashboard: The current KPIs (revenue, margins, long-term contract amounts) should be expanded to include:

    • Project margin variance (estimated vs. actual)
    • Cash conversion cycle
    • Backlog quality (percentage of backlog at target margins)
    • Employee utilisation rates

Summary

Protec Camerfield is a company in recovery from a severe financial illness, kept alive through parental life support in the form of £7m in capital injections over two years. The vital signs are improving — revenue is growing, gross margins have moved from deeply negative to slightly positive, and costs have been substantially reduced. However, the patient remains fragile: operating losses persist, leverage is dangerously high, and the business is still dependent on its parent for financial survival. The strategic pivot toward mechanical suppression services and smaller projects is the correct prescription, but the prognosis depends entirely on execution discipline and the continued support of the Bosch Group parent.